Canopy Growth (WEED) Competitors C$1.48 +0.05 (+3.50%) As of 01:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock WEED vs. MJN, CMED, EMC, ICC, and OGIShould you buy Canopy Growth stock or one of its competitors? MarketBeat compares Canopy Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Canopy Growth include Cronos Group (MJN), CanniMed Therapeutics (CMED), Emblem (EMC), ICC Labs (ICC), and Organigram (OGI). These companies are all part of the "cannabis" industry. WEED vs. MJNWEED vs. CMEDWEED vs. EMCWEED vs. ICCWEED vs. OGIHow does Canopy Growth compare to Cronos Group?Cronos Group (CVE:MJN) and Canopy Growth (TSE:WEED) are both small-cap cannabis companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation. Does the media prefer MJN or WEED? In the previous week, Canopy Growth had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score. Company Overall Sentiment Cronos Group Neutral Canopy Growth Neutral Do institutionals & insiders have more ownership in MJN or WEED? 3.6% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, MJN or WEED? Cronos Group has higher earnings, but lower revenue than Canopy Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos GroupN/AN/AN/AN/AN/ACanopy GrowthC$278.39M2.25-C$1.05B-C$1.86N/A Do analysts prefer MJN or WEED? Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 32.88%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is MJN or WEED more profitable? Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -117.31%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Cronos GroupN/A N/A N/A Canopy Growth -117.31%-52.88%-3.83% SummaryCanopy Growth beats Cronos Group on 7 of the 10 factors compared between the two stocks.How does Canopy Growth compare to CanniMed Therapeutics?CanniMed Therapeutics (TSE:CMED) and Canopy Growth (TSE:WEED) are both small-cap cannabis companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability. Which has preferable earnings and valuation, CMED or WEED? CanniMed Therapeutics has higher earnings, but lower revenue than Canopy Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanniMed TherapeuticsN/AN/AN/AN/AN/ACanopy GrowthC$278.39M2.25-C$1.05B-C$1.86N/A Do analysts recommend CMED or WEED? Canopy Growth has a consensus price target of C$1.97, suggesting a potential upside of 32.88%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than CanniMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is CMED or WEED more profitable? CanniMed Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -117.31%. CanniMed Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets CanniMed TherapeuticsN/A N/A N/A Canopy Growth -117.31%-52.88%-3.83% Does the media favor CMED or WEED? In the previous week, Canopy Growth had 1 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for CanniMed Therapeutics. CanniMed Therapeutics' average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score. Company Overall Sentiment CanniMed Therapeutics Neutral Canopy Growth Neutral Do institutionals and insiders believe in CMED or WEED? 3.6% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryCanopy Growth beats CanniMed Therapeutics on 7 of the 10 factors compared between the two stocks.How does Canopy Growth compare to Emblem?Canopy Growth (TSE:WEED) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Do analysts rate WEED or EMC? Canopy Growth presently has a consensus price target of C$1.97, indicating a potential upside of 32.88%. Given Canopy Growth's stronger consensus rating and higher possible upside, research analysts plainly believe Canopy Growth is more favorable than Emblem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Emblem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is WEED or EMC more profitable? Emblem has a net margin of 0.00% compared to Canopy Growth's net margin of -117.31%. Emblem's return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-117.31% -52.88% -3.83% Emblem N/A N/A N/A Do insiders & institutionals believe in WEED or EMC? 3.6% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, WEED or EMC? Emblem has lower revenue, but higher earnings than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy GrowthC$278.39M2.25-C$1.05B-C$1.86N/AEmblem$5.71M43.02-$24.81M-$0.19N/A Does the media prefer WEED or EMC? In the previous week, Canopy Growth had 1 more articles in the media than Emblem. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for Emblem. Canopy Growth's average media sentiment score of 0.00 equaled Emblem'saverage media sentiment score. Company Overall Sentiment Canopy Growth Neutral Emblem Neutral SummaryCanopy Growth beats Emblem on 8 of the 14 factors compared between the two stocks.How does Canopy Growth compare to ICC Labs?ICC Labs (CVE:ICC) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Is ICC or WEED more profitable? ICC Labs has a net margin of 0.00% compared to Canopy Growth's net margin of -117.31%. ICC Labs' return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets ICC LabsN/A N/A N/A Canopy Growth -117.31%-52.88%-3.83% Do institutionals & insiders have more ownership in ICC or WEED? 3.6% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer ICC or WEED? In the previous week, Canopy Growth had 1 more articles in the media than ICC Labs. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for ICC Labs. ICC Labs' average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score. Company Overall Sentiment ICC Labs Neutral Canopy Growth Neutral Do analysts prefer ICC or WEED? Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 32.88%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than ICC Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ICC Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has better valuation and earnings, ICC or WEED? ICC Labs has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioICC LabsC$533.68K419.04C$2.35MC$0.0295.29Canopy GrowthC$278.39M2.25-C$1.05B-C$1.86N/A SummaryICC Labs and Canopy Growth tied by winning 7 of the 14 factors compared between the two stocks.How does Canopy Growth compare to Organigram?Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability. Do institutionals & insiders believe in WEED or OGI? 3.6% of Canopy Growth shares are held by institutional investors. Comparatively, 4.0% of Organigram shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Comparatively, 31.3% of Organigram shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer WEED or OGI? In the previous week, Canopy Growth and Canopy Growth both had 1 articles in the media. Canopy Growth's average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organigram 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate WEED or OGI? Canopy Growth currently has a consensus price target of C$1.97, suggesting a potential upside of 32.88%. Organigram has a consensus price target of C$3.13, suggesting a potential upside of 101.61%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, WEED or OGI? Organigram has lower revenue, but higher earnings than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy GrowthC$278.39M2.25-C$1.05B-C$1.86N/AOrganigramC$274.19M0.80-C$57.23M-C$0.21N/A Which has more volatility & risk, WEED or OGI? Canopy Growth has a beta of 1.605535, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Organigram has a beta of 1.722534, meaning that its stock price is 72% more volatile than the broader market. Is WEED or OGI more profitable? Organigram has a net margin of -9.19% compared to Canopy Growth's net margin of -117.31%. Organigram's return on equity of -6.83% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-117.31% -52.88% -3.83% Organigram -9.19%-6.83%-5.56% SummaryOrganigram beats Canopy Growth on 9 of the 13 factors compared between the two stocks. Get Canopy Growth News Delivered to You Automatically Sign up to receive the latest news and ratings for WEED and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WEED vs. The Competition ExportMetricCanopy GrowthDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$625.77MC$2.15BC$6.30BC$11.94BDividend Yield4.80%2.96%2.80%6.23%P/E Ratio-0.805.3920.7937.37Price / Sales2.251,674.83518.7911.43Price / Cash1.6310.1843.1882.29Price / Book0.6710.439.964.39Net Income-C$1.05BC$20.70BC$3.54BC$299.09M7 Day PerformanceN/A-0.91%-0.19%-1.22%1 Month Performance-5.13%-4.03%-0.63%0.69%1 Year Performance-40.32%23.31%34.10%53.47% Canopy Growth Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WEEDCanopy Growth1.9688 of 5 starsC$1.48+3.5%C$1.97+32.9%-41.2%C$625.77MC$278.39MN/A2,700MJNCronos GroupN/AC$12.15-1.9%N/A+0.0%C$1.73BN/AN/A7,600CMEDCanniMed TherapeuticsN/AN/AN/AN/AC$668.44MN/AN/A147,000EMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71MN/AN/AICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533.68K95.29N/AGap Up Related Companies and Tools Related Companies Cronos Group Alternatives CanniMed Therapeutics Alternatives Emblem Alternatives ICC Labs Alternatives Organigram Alternatives Leaf Mobile Alternatives Maple Leaf Green World Alternatives Beleave Alternatives Cannabix Technologies Alternatives Supreme Cannabis Company Inc, Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:WEED) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Canopy Growth Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Canopy Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
